Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,405 across all filing types
Latest filing 2018-10-01 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Total Voting Rights
Regulatory Filings Classification · 98% confidence The document explicitly starts with an 'RNS Number' and is dated 01 October 2018. The content discusses 'Voting Rights and Capital' and references the 'UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1', detailing the total number of voting rights (1,266,784,907). This type of mandatory, periodic disclosure regarding share capital and voting rights, distributed via the London Stock Exchange's news service (RNS), fits best under the general regulatory announcement category. While it relates to capital, it is a specific regulatory notification rather than a financing activity (CAP) or a share repurchase (POS). Given the source (RNS Number) and the nature of the disclosure (voting rights denominator), the most appropriate classification is RNS, the general regulatory filing category, as it is a standard regulatory update distributed through that channel.
2018-10-01 English
ATACAND AGREEMENT WITH CHEPLAPHARM COMPLETED
Regulatory Filings
2018-10-01 English
Atacand Agreement with Cheplapharm Completed
M&A Activity Classification · 99% confidence The document explicitly starts with an 'RNS Number' and contains contact information for Media Relations and Investor Relations, concluding with a statement that the information is provided by RNS, the news service of the London Stock Exchange, which is approved by the FCA. This structure is characteristic of a regulatory news service announcement. The content describes the completion of a commercial agreement (M&A/Asset Sale related), which is a material event requiring immediate disclosure. Since it is a general regulatory announcement disseminated via RNS and does not fit neatly into specific categories like M&A Activity (TAR) or Capital Change (CAP), the most appropriate classification is the general regulatory filing category, RNS.
2018-10-01 English
Previous Announcement Regarding Appointment Of NED
Regulatory Filings Classification · 98% confidence The document is explicitly marked with an 'RNS Number' and contains contact information related to the London Stock Exchange's news service ('RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider'). The content announces a change regarding a proposed appointment to the Board of Directors (withdrawal of candidacy for Non-Executive Director). This type of announcement, which is a regulatory update distributed via the RNS system and concerns board composition, fits best under the 'Board/Management Information' (MANG) category. Although it is distributed via RNS, the core subject matter is management change, which is more specific than the general 'RNS' fallback.
2018-09-28 English
PREVIOUS ANNOUNCEMENT REGARDING APPOINTMENT OF NED
Regulatory Filings
2018-09-28 English
FORM 3 SUBMISSION
Director's Dealing
2018-09-26 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.